Novo Holdings completed the acquisition of BBI Group from Exponent for £400m.

Novo Holdings, a global life sciences investor, completed the acquisition of BBI Group, a supplier of products and services to the global diagnostics and life sciences industries, from Exponent, a private equity firm, for c.£400m ($564m). "We see tremendous opportunities for both organic and inorganic growth for the company. Novo Holdings is looking forward to contributing its considerable industry expertise and extensive network in supporting the talented team at BBI," Johan Hueffer, Novo Holdings Senior Partner.